Blog and Whitepapers
Recon takes an analytical look behind select developments in healthcare
- By Marc Herant
Preempting severe genetic disease
Around 2% of births come with a genetic disease, often with devastating impact. While some appear de novo (either from germplasm dominant mutations or from chromosomal accidents), a fraction are inherited (from the mother if X-linked, from both parents if autosomal recessive) and can be predicted (before conception) by gene sequencing parents. In a fascinating stu…
Keep up with the Recon Strategy Insights
Get an email each time Recon takes an analytical look behind select developments in healthcare.
- By Marc Herant
An innovative modality to suppress PCSK9
Antisense technology relies on the concept that it is possible to interfere with the cellular genetic machinery in very specific ways by deploying short RNA se…
- By Jason Brauner
The public debate on drug pricing has sharpened markedly over the past year. We are seeing more political scrutiny and media coverage, including the blowback on Mylan’s EpiPen pricing, tweets from now…
- By Marc Herant
Successful use of CAR-T therapy in a solid tumor
Chimeric Antigen Reception T-cells (CAR-T) are immune cells molecularly engineered to seek out and destroy cancer cells; the push to develop them into …
- By Marc Herant
“My name is T-Cell…, James T-Cell”
Immune T-cells are licensed to kill other cells through a quick molecular kiss of death, and as such are potentially powerful allies in controlling a tumor. For obvi…
- By Marc Herant
I am not sure how many docs continue to do this, but I still read the actual hard copy of my NEJM, and that means I flip past ad pages with smiling grandfathers playing with grandchildren thanks to su…
- By Marc Herant
Continued progress in multiple myeloma
About 25,000 patients are diagnosed with multiple myeloma yearly in the US. Despite being initially treatable, typically this disease is ultimately lethal. Follo…
- By Marc Herant
Taking a page from HIV to build a response to opioid abuse
A couple of perspectives on the challenges of treating individuals who suffer from opioid dependence. The first highlights the importance of …
- By Marc Herant
There is such a thing as too much hygiene
The prevalence of asthma in children has increased dramatically over the last few decades. Observational studies have shown that children in “dirty” environme…
- By Tory Wolff
Summary
Cheap home devices are starting to generate a flood of high frequency, low latency biometric data, much of it of uncertain clinical value
This uncertainty makes designing the service model di…
- By Marc Herant
Adaptive clinical trials slowly coming of age
In an adaptive clinical trial, the protocol of the trial is allowed to change in a pre-specified manner during the study based on on-going study events. …
- By Marc Herant
Disappointing interim results from two ACA experiments
Two papers reporting results from ACA experiments – the Comprehensive Primary Care (CPC) Initiative in which primary practices were incentivized …
- By Tory Wolff
Summary
Livongo is marrying a cellular-enabled glucometer and a data cloud with patient engagement services to help manage sugar levels
Glucometer incumbents could match Livongo’s technology but will…
Search
Authors